|
1
|
Chen L, Yang J, Zheng M, Kong X, Huang T
and Cai YD: The use of chemical-chemical interaction and chemical
structure to identify new candidate chemicals related to lung
cancer. PLoS One. 10:e01286962015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee H, Hwang SJ, Jung J, Hong S, Lee M,
Park HG, Lee HJ and Park Y: Asymmetric synthesis and evaluation of
α-quaternary chiral lactam derivatives as novel anticancer agents.
Arch Pharm Res. 37:1264–1270. 2014. View Article : Google Scholar
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galliford CV and Scheidt KA:
Pyrrolidinyl-spirooxindole natural products as inspirations for the
development of potential therapeutic agents. Angew Chem Int Ed
Engl. 46:8748–8758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen G, Weng Q, Fu L, Wang Z, Yu P, Liu Z,
Li X, Zhang H and Liang G: Synthesis and biological evaluation of
novel oxindole-based RTK inhibitors as anti-cancer agents. Bioorg
Med Chem. 22:6953–6960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Natarajan A, Guo Y, Harbinski F, Fan YH,
Chen H, Luus L, Diercks J, Aktas H, Chorev M and Halperin JA: Novel
arylsulfoanilide-oxindole hybrid as an anticancer agent that
inhibits translation initiation. J Med Chem. 47:4979–4982. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Silva BV, Ribeiro NM, Vargas MD,
Lanznaster M, Carneiro JW, Krogh R, Andricopulo AD, Dias LC and
Pinto AC: Synthesis, electrochemical studies and anticancer
activity of ferrocenyl oxindoles. Dalton Trans. 39:7338–7344. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kamal A, Ramakrishna G, Raju P, Rao AV,
Viswanath A, Nayak VL and Ramakrishna S: Synthesis and anticancer
activity of oxindole derived imidazo[1,5-a]pyrazines. Eur J Med
Chem. 46:2427–2435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cui CB, Kakeya H and Osada H:
Spirotryprostatin B, a novel mammalian cell cycle inhibitor
produced by Aspergillus fumigatus. J Antibiot (Tokyo). 49:832–835.
1996. View Article : Google Scholar
|
|
10
|
Papaetis GS and Syrigos KN: Sunitinib: A
multitargeted receptor tyrosine kinase inhibitor in the era of
molecular cancer therapies. BioDrugs. 23:377–389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang WL, Conley A, Reynoso D, Nolden L,
Lazar AJ, George S and Trent JC: Mechanisms of resistance to
imatinib and sunitinib in gastrointestinal stromal tumor. Cancer
Chemother Pharmacol. 67(Suppl 1): S15–S24. 2011. View Article : Google Scholar
|
|
12
|
Kussie PH, Gorina S, Marechal V, Elenbaas
B, Moreau J, Levine AJ and Pavletich NP: Structure of the MDM2
oncoprotein bound to the p53 tumor suppressor transactivation
domain. Science. 274:948–953. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S,
Ding Y, Gao W, Stuckey J, Krajewski K, Roller PP, Tomita Y, et al:
Structure-based design of potent non-peptide MDM2 inhibitors. J Am
Chem Soc. 127:10130–10131. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding K, Lu Y, Nikolovska-Coleska Z, Wang
G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K, et al:
Structure-based design of spiro-oxindoles as potent, specific
small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem.
49:3432–3435. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park Y, Lee YJ, Hong S, Lee M and Park HG:
Highly enantioselective total synthesis of (+)-isonitramine. Org
Lett. 14:852–854. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reed SM and Quelle DE: p53 Acetylation:
Regulation and consequences. Cancers (Basel). 7:30–69. 2014.
View Article : Google Scholar
|
|
17
|
Melvin AT, Dumberger LD, Woss GS, Waters
ML and Allbritton NL: Identification of a p53-based portable degron
based on the MDM2-p53 binding region. Analyst (Lond). 141:570–578.
2016. View Article : Google Scholar
|
|
18
|
Huang KY, Weng JT, Lee TY and Weng SL: A
new scheme to discover functional associations and regulatory
networks of E3 ubiquitin ligases. BMC Syst Biol. 10(Suppl 1):
32016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Richmond J, Carol H, Evans K, High L,
Mendomo A, Robbins A, Meyer C, Venn NC, Marschalek R, Henderson M,
et al: Effective targeting of the P53-MDM2 axis in preclinical
models of infant MLL-rearranged acute lymphoblastic leukemia. Clin
Cancer Res. 21:1395–1405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saiki AY, Caenepeel S, Cosgrove E, Su C,
Boedigheimer M and Oliner JD: Identifying the determinants of
response to MDM2 inhibition. Oncotarget. 6:7701–7712. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deben C, Wouters A, Op de Beeck K, van Den
Bossche J, Jacobs J, Zwaenepoel K, Peeters M, Van Meerbeeck J,
Lardon F, Rolfo C, et al: The MDM2-inhibitor Nutlin-3 synergizes
with cisplatin to induce p53 dependent tumor cell apoptosis in
non-small cell lung cancer. Oncotarget. 6:22666–22679. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zanjirband M, Edmondson RJ and Lunec J:
Pre-clinical efficacy and synergistic potential of the MDM2-p53
antagonists, Nutlin-3 and RG7388, as single agents and in combined
treatment with cisplatin in ovarian cancer. Oncotarget. May
20–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Michaelis M, Rothweiler F, Barth S, Cinatl
J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling
A, Rödel F, et al: Adaptation of cancer cells from different
entities to the MDM2 inhibitor nutlin-3 results in the emergence of
p53-mutated multi-drug-resistant cancer cells. Cell Death Dis.
2:e2432011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rennekamp AJ and Peterson RT: 15 years of
zebrafish chemical screening. Curr Opin Chem Biol. 24:58–70. 2015.
View Article : Google Scholar
|
|
25
|
Sun Y, Sheng Z, Ma C, Tang K, Zhu R, Wu Z,
Shen R, Feng J, Wu D, Huang D, et al: Combining genomic and network
characteristics for extended capability in predicting synergistic
drugs for cancer. Nat Commun. 6:84812015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Z and Liu F: Cautious use of
fli1a:EGFP transgenic zebrafish in vascular research. Biochem
Biophys Res Commun. 427:223–226. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barriuso J, Nagaraju R and Hurlstone A:
Zebrafish: A new companion for translational research in oncology.
Clin Cancer Res. 21:969–975. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eden CJ, Ju B, Murugesan M, Phoenix TN,
Nimmervoll B, Tong Y, Ellison DW, Finkelstein D, Wright K, Boulos
N, et al: Orthotopic models of pediatric brain tumors in zebrafish.
Oncogene. 34:1736–1742. 2015. View Article : Google Scholar
|
|
29
|
Gonçalves AS, Macedo AS and Souto EB:
Therapeutic nanosystems for oncology nanomedicine. Clin Transl
Oncol. 14:883–890. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yin Q, Shen J, Zhang Z, Yu H, Chen L, Gu W
and Li Y: Multi-functional nanoparticles improve therapeutic effect
for breast cancer by simultaneously antagonizing multiple
mechanisms of multidrug resistance. Biomacromolecules.
14:2242–2252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ribeiro CJ, Amaral JD, Rodrigues CM,
Moreira R and Santos MM: Synthesis and evaluation of
spiroisoxazoline oxindoles as anticancer agents. Bioorg Med Chem.
22:577–584. 2014. View Article : Google Scholar
|
|
32
|
Shangary S, Ding K, Qiu S,
Nikolovska-Coleska Z, Bauer JA, Liu M, Wang G, Lu Y, McEachern D,
Bernard D, et al: Reactivation of p53 by a specific MDM2 antagonist
(MI-43) leads to p21-mediated cell cycle arrest and selective cell
death in colon cancer. Mol Cancer Ther. 7:1533–1542. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jensen BS: BMS-204352: A potassium channel
opener developed for the treatment of stroke. CNS Drug Rev.
8:353–360. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen G, Jiang L, Dong L, Wang Z, Xu F,
Ding T, Fu L, Fang Q, Liu Z, Shan X, et al: Synthesis and
biological evaluation of novel indole-2-one and 7-aza-2-oxindole
derivatives as anti-inflammatory agents. Drug Des Devel Ther.
8:1869–1892. 2014.PubMed/NCBI
|
|
35
|
Sun Y, Liu J, Jiang X, Sun T, Liu L, Zhang
X, Ding S, Li J, Zhuang Y, Wang Y, et al: One-step synthesis of
chiral oxindole-type analogues with potent anti-inflammatory and
analgesic activities. Sci Rep. 5:136992015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ho HK, Chua BT, Wong W, Lim KS, Teo V, Ong
HT, Chen X, Zhang W, Hui KM, Go ML, et al: Benzylidene-indolinones
are effective as multi-targeted kinase inhibitor therapeutics
against hepatocellular carcinoma. Mol Oncol. 8:1266–1277. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Izzedine H, Buhaescu I, Rixe O and Deray
G: Sunitinib malate. Cancer Chemother Pharmacol. 60:357–364. 2007.
View Article : Google Scholar
|
|
38
|
Engeland K: Simplify p53: Just an
activator. Oncotarget. 6:3–4. 2015.PubMed/NCBI
|
|
39
|
Koshino A, Goto-Koshino Y, Setoguchi A,
Ohno K and Tsujimoto H: Mutation of p53 gene and its correlation
with the clinical outcome in dogs with lymphoma. J Vet Intern Med.
30:223–229. 2016. View Article : Google Scholar :
|
|
40
|
Hellesøy M and Lorens JB: Cellular
context-mediated Akt dynamics regulates MAP kinase signaling
thresholds during angiogenesis. Mol Biol Cell. 26:2698–2711. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang JJ, Shi YQ, Li RL, Hu A, Lu ZY, Weng
L, Wang SQ, Han YP, Zhang L, Li B, et al: Angiogenesis effect of
therapeutic ultrasound on HUVECs through activation of the
PI3K-Akt-eNOS signal pathway. Am J Transl Res. 7:1106–1115.
2015.PubMed/NCBI
|
